Male BRCA1 and BRCA2 mutation carriers: A pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic
Male BRCA1 and BRCA2 mutation carriers: A pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic
复制标题
DOI：
10.1002/pros.20278
复制
发表时间：
2005-10-01
期刊：
影响因子：
2.8
通讯作者：
Trachtenberg, J
中科院分区：
文献类型：
--
作者：
Horsburgh, S;Matthew, A;Trachtenberg, J
背景男性BRCA1和BRCA2突变携带者患前列腺癌的风险增加，并接受高危男性筛查方案。靶向筛查的效用以及与前列腺癌相关的临床和病理特征在这一人群中很少受到关注。我们报告了一组19名BRCA1或BRCA2突变男性的临床筛查和病理特征，并与年龄匹配的有前列腺癌家族史的男性进行了比较。突变携带者在首次就诊时PSA升高的可能性更大（P = 0.03）。突变携带者诊断为前列腺癌的可能性是突变携带者的两倍，尽管这种差异没有统计学意义（P = 0.55）。BRCA1和BRCA2突变携带者的前列腺癌监测是必要的。需要对更大的队列进行进一步研究，以评估这些男性中是否存在独特的病理前列腺癌特征。
BACKGROUND. Male BRCA1 and BRCA2 mutation carriers are at an increased risk to develop prostate cancer and are subject to screening protocols for high-risk men. The utility of targeted screening, and the clinical and pathological features associated with prostate cancer, have received little attention in this population.METHODS. We report on the clinical screening and pathological characteristics of a group of 19 men with BRCA1 or BRCA2 mutation, as compared to an age-matched group of men with a family history of prostate cancer.RESULTS. Mutation carriers were significantly more likely to have an elevated PSA at first visit (P = 0.03). Prostate cancer was twice as likely to be diagnosed in mutation carriers although this difference was not statistically significant (P = 0.55).CONCLUSIONS. Prostate cancer surveillance of BRCA1 and BRCA2 mutation carriers is warranted. Further research on larger cohorts is needed to evaluate whether unique pathological prostate cancer characteristics exist in these men.